Carotuximab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Carotuximab (TRC105) 是一种 IgG1 单克隆抗体，可阻断内皮糖蛋白 (CD105) 及其下游 Smad 信号通路。Carotuximab 具有免疫调节和抗肿瘤作用。

Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions.

Western Blot Analysis Cell Line:Human aortic endothelial cells (HAoECs) Concentration:300 μg/mL Incubation Time:Pretreatment 1 h, and then co-cultured for 12 h Result:Reduced the 7-Ketocholesterol-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling.

Animal Model:Female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; 7-8 weeks) injected with primary AML-0032 cells Dosage:2 mg/kg Administration:i.v; every 3 days; for 8 weeks Result:Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts.

——

Others

Other Targets

TGF-beta/Smad | Immunology/Inflammation related

——

——

1268714-50-6

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years